Novartis reinvested in Annexon, which is developing treatments for neurodegenerative diseases, and which has now raised $79m in total.

A joint venture co-founded by China-headquartered Jiangsu Hengrui Medicine has provided $100m to an oncology startup named Hengrui Therapeutics.

Imstar gets the backing of BDC Capital and Accel-Rx in advancing its preclinical work on its potential treatment for Lou Gehrig's disease (ALS) in a $1.8m seed round.

EIF invests in the tech transfer fund of Groningen University and UMCG to support innovation in northern areas of the Netherlands and the healthy ageing sector.

Novartis has supplied cash to IFM Therapeutics' $27m series A round to help the biopharmaceutical company's efforts to develop a cancer treatment.

Sanofi-backed Selecta Biosciences had raised $117m prior to the offering, and will use the proceeds to advance its gout treatment through clinical trials.

The medication tracking and kit processing software provider secured funding in a series C round led by Baxter Ventures that included Kaiser Permanente.

Thuja Capital Healthcare Fund II will support commercialisation of research at Utrecht University, University Medical Center Utrecht and Radboud University Medical Center.

Legend Capital, one of conglomerate Legend Holdings' investment units, has co-led a series B round for medical device supply chain services provider Guoke Hengtai.